[1] European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol,2017,67:370-398.
[2] 汪涛,刘娟,王婵,等.HBV DNA联合ALT对HBeAg阴性慢性活动性乙型肝炎的诊断价值.中国中西医结合消化杂志,2016,24:582-585.
[3] 杜克先.慢性乙型肝炎诊断中的常规生化、血常规及生化新指标检验项目价值分析.国际检验医学杂志,2016,37:3353-3355.
[4] Terrault NA,Bzowej NH,Chang KM,et al.American Association for the Study of Liver Diseases.AASLD guidelines for treatment of chronic hepatitis B.Hepatology,2016,63:261-283.
[5] Sarin SK,Kumar M,Lau GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update.Hepatol Int,2016,10:1-98.
[6] World Health Organization.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection.2015.
[7] 胡晨波,陆培瑜,陈晓蓉.HBsAg定量在慢性乙型肝炎自然史及干扰素治疗中的临床意义.肝脏,2014,19:74-76.
[8] Liu C,Wu W,Shang H,et al.Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients.Clin Chim Acta,2018,481:12-19.
[9] 田婧,何岩莉,骈林萍,等.声触诊组织量化联合天门冬氨酸氨基转移酶/血小板比值对慢性乙型肝炎患者肝纤维化分期的诊断价值研究.实用肝脏病杂志,2018,21:216-219. |
